CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report)'s stock price rose 0.8% during mid-day trading on Thursday . The stock traded as high as $42.58 and last traded at $41.55. Approximately 382,212 shares were traded during mid-day trading, a decline of 80% from the average daily volume of 1,904,722 shares. The stock had previously closed at $41.21.
Wall Street Analyst Weigh In
Several research firms have issued reports on CRSP. Chardan Capital reaffirmed a "buy" rating and set a $94.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. StockNews.com raised shares of CRISPR Therapeutics to a "sell" rating in a research report on Monday, December 30th. Barclays reduced their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating on the stock in a research note on Wednesday, November 6th. JMP Securities reaffirmed a "market outperform" rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Finally, Needham & Company LLC restated a "buy" rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, January 14th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $78.38.
View Our Latest Stock Analysis on CRISPR Therapeutics
CRISPR Therapeutics Price Performance
The firm's fifty day moving average price is $43.97 and its 200-day moving average price is $47.42. The company has a market cap of $3.59 billion, a price-to-earnings ratio of -14.86 and a beta of 1.68.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.41. The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same quarter last year, the business earned ($1.41) earnings per share. As a group, equities analysts forecast that CRISPR Therapeutics AG will post -5.13 earnings per share for the current fiscal year.
Insider Buying and Selling at CRISPR Therapeutics
In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 30,000 shares of the business's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the sale, the chief executive officer now directly owns 196,540 shares in the company, valued at approximately $10,931,554.80. The trade was a 13.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.10% of the stock is owned by company insiders.
Institutional Investors Weigh In On CRISPR Therapeutics
A number of institutional investors have recently added to or reduced their stakes in CRSP. Highline Wealth Partners LLC acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at $39,000. Western Pacific Wealth Management LP raised its position in CRISPR Therapeutics by 100.0% in the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after acquiring an additional 500 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in CRISPR Therapeutics in the 3rd quarter valued at about $40,000. Darwin Wealth Management LLC acquired a new position in shares of CRISPR Therapeutics in the 3rd quarter worth approximately $43,000. Finally, Eastern Bank bought a new stake in shares of CRISPR Therapeutics in the 3rd quarter worth approximately $70,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.
About CRISPR Therapeutics
(
Get Free Report)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for February 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
